Greenleaf Trust purchased a new stake in Chemed Co. (NYSE:CHE) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 839 shares of the company’s stock, valued at approximately $268,000.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Fort L.P. acquired a new stake in Chemed in the 2nd quarter valued at $120,000. Cerebellum GP LLC acquired a new stake in Chemed in the 3rd quarter valued at $148,000. Tower Research Capital LLC TRC grew its position in Chemed by 70.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 544 shares of the company’s stock valued at $175,000 after purchasing an additional 224 shares during the period. We Are One Seven LLC acquired a new stake in Chemed in the 3rd quarter valued at $228,000. Finally, Hollencrest Capital Management acquired a new stake in Chemed in the 3rd quarter valued at $231,000. 89.92% of the stock is owned by institutional investors and hedge funds.
CHE has been the subject of several research reports. Royal Bank of Canada lifted their price target on shares of Chemed to $321.00 and gave the company a “market perform” rating in a research report on Monday, July 30th. Zacks Investment Research raised shares of Chemed from a “hold” rating to a “buy” rating and set a $350.00 price target for the company in a research report on Tuesday, July 31st. ValuEngine cut Chemed from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 2nd. Finally, Bank of America initiated coverage on Chemed in a research note on Friday, October 12th. They set a “buy” rating and a $390.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Chemed has an average rating of “Buy” and an average target price of $334.00.
In other Chemed news, Director Donald E. Saunders sold 300 shares of the firm’s stock in a transaction on Monday, August 20th. The stock was sold at an average price of $319.22, for a total transaction of $95,766.00. Following the transaction, the director now directly owns 8,701 shares in the company, valued at approximately $2,777,533.22. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin J. Mcnamara sold 4,000 shares of the firm’s stock in a transaction on Thursday, August 23rd. The shares were sold at an average price of $319.50, for a total value of $1,278,000.00. Following the transaction, the insider now owns 139,491 shares in the company, valued at $44,567,374.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,006 shares of company stock worth $1,923,098. Company insiders own 4.90% of the company’s stock.
Shares of NYSE:CHE opened at $306.93 on Friday. The company has a current ratio of 1.14, a quick ratio of 1.01 and a debt-to-equity ratio of 0.23. Chemed Co. has a 1-year low of $227.14 and a 1-year high of $335.99. The firm has a market cap of $4.90 billion, a price-to-earnings ratio of 26.79, a P/E/G ratio of 2.73 and a beta of 1.22.
Chemed (NYSE:CHE) last issued its quarterly earnings data on Monday, October 29th. The company reported $3.07 earnings per share for the quarter, beating the consensus estimate of $2.80 by $0.27. Chemed had a return on equity of 35.13% and a net margin of 11.73%. The business had revenue of $444.15 million for the quarter, compared to analysts’ expectations of $445.16 million. During the same period last year, the business earned $2.15 EPS. The business’s revenue was up 6.4% on a year-over-year basis. As a group, sell-side analysts forecast that Chemed Co. will post 11.41 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Monday, November 12th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 0.39%. Chemed’s dividend payout ratio (DPR) is presently 22.39%.
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Featured Article: Average Daily Trade Volume Explained
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.